Delivery Order SPE2DR25D3109-SPE2DR26FT2JZ
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,458.10 on December 5, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pen injections. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the company's distribution facility in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injections, valued at $6,035.72. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist...
- The Defense Logistics Agency awarded a $5,621.91 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections with an ultimate completion date of September 17, 2025. This firm fixed price contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $4,909.94 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injections on December 16, 2025, with completion scheduled for December 17, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound, a GLP-1 receptor agonist used for weight management, represents...
- The Defense Logistics Agency awarded a delivery order valued at $1,071.60 to AmerisourceBergen Drug Corp for Zepbound 15 mg/0.5 mL pen injections on September 25, 2025. This firm fixed-price delivery order, which was competitively awarded without set-aside designation, will be performed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of September 26, 2025. Zepbound is a GLP-1 receptor agonist used for weight management and is part of the broader...
- The Defense Logistics Agency awarded a delivery order valued at $22,101.88 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 ml pen injectors (0.5 ml). This firm fixed-price, non-set-aside delivery order was awarded on December 2, 2025, with an ultimate completion date of December 3, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used in the treatment of obesity and...
- The Defense Logistics Agency awarded a delivery order valued at $35,090.09 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pen injections on December 4, 2025, with completion scheduled for December 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound, a GLP-1 receptor agonist used for weight management, represents one of many...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on December 8, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injections with a ceiling value of $2,214.84. This is a firm fixed-price delivery order with an ultimate completion date of December 9, 2025, and carries no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 17, 2025, for $5,735.03 to supply Zepbound 2.5 mg/0.5 mL pen injections. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of December 18, 2025. The product will be delivered to AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $28,427.31 to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 ml pen injections on December 12, 2025, with a completion date of December 15, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DR25D3109Indefinite Delivery Contract
- SPE2DR25D3109-SPE2DR26FT2JZDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,077.99 to AmerisourceBergen Drug Corp for the supply of Zepbound 15 mg/0.5 ml pen injections on December 17, 2025. This is a firm fixed price delivery order with no set-aside designation, utilizing competitive procurement procedures. The contract is set to be completed by December 18, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound, a GLP-1 receptor agonist indicated for weight management, represents one of the specialized pharmaceutical products within the federal medical supply portfolio. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime vehicle provides comprehensive global pharmaceutical support across multiple therapeutic domains to military healthcare programs, the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, has demonstrated consistent capability to fulfill federal medical procurement requirements through open competition, with this contract reflecting the company's ongoing role as a critical vendor within the DLA Medical Supply Chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 12/16/25 |